Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized bismuth plus triple therapy for first-line Helicobacter pylori eradication
ChiCTR-IPR-17012876Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bismuth subsalicylate in Helicobacter pylori infection (3 arms), sponsored by Peking University Third Hospital. Primary endpoint: Eradication rate. Planned start Oct 2017; status: not yet recruiting.
02
Drugs
bismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR-IPR-17012876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012876.